Publications by authors named "Maria Rubinacci"
Article Synopsis
- Pexidartinib is a drug used for treating tenosynovial giant cell tumor (TGCT) in patients where surgery isn't an option, and this study looked at the effects of stopping and then restarting the medication.
- It was a phase 4 global study involving patients who had benefited from pexidartinib, allowing them to either continue treatment or stop with the option to restart later, monitoring their tumor progression and quality of life.
- Results showed that while about 54.5% of patients who stopped the drug experienced disease progression, none of those who continued treatment saw their condition worsen over a 24-month period.
Background: Antidepressants (AD) need to be chronically administered (weeks to months) to provide beneficial effects. Evidence suggests that combined administration of inhibitors of monoamine reuptake and phosphodiesterase type 4 allows a highly effective therapeutic action. Also, this coadministration more rapidly boosts the cyclic adenosine monophosphate (cAMP) pathway, which is normally activated during chronic treatment of single compounds.
View Article and Find Full Text PDF